TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00904917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Intervention Project
Description: Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
Study: NCT01082796

Intervention type: DRUG
Group type: OTHER
Intervention: Glipizide
Description: Each subject received 5 mg glipizide extended release tablet once daily for 7 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Glipizide
Description: Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
Study: NCT04586465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin
Description: Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles
Study: NCT03307187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLB Adapted for Individuals with Impaired Mobility
Description: The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
Study: NCT04247451

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Metabolic profile and nutritional goals in diabetic foot surgery patients
Description: Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants.
Study: NCT01066793

Intervention type: DRUG
Intervention: Peginterferon alfa-2a [Pegasys]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.

Intervention type: DRUG
Intervention: Peginterferon alfa-2b [PegIntron®]
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study: NCT03102671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of HeartHab application followed by usual care
Description: use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care followed by the use of HeartHab application
Description: Usual care (2 months) followed by the use of HeartHab application (two months)
Study: NCT05033977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise (center-based)
Description: Exercise therapy with a physical therapist in a clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise (home-based)
Description: Patients did exercises at home every day and 3 times per day.
Study: NCT04465656

Intervention type: DIAGNOSTIC_TEST
Intervention: Serology test for COVID-19
Description: In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~1. ELISA test~2. Rapid Diagnostic tests (only if ELISA test is positive)
Study: NCT03550547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational workshops
Description: 1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa Therapy
Description: Approved Spa therapy of knee osteoarthritis patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spa Therapy
Description: Approved Spa therapy of knee osteoarthritis patients
Study: NCT03774394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel active metabolite
Description: In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel active metabolite
Description: In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
Study: NCT05668572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
Description: 0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）
Description: 0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
Study: NCT00824707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 0.5mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy including protecting the liver function, anti-tumor and so on
Study: NCT02376205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine hydrochloride 0.5% solution
Description: 10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl solution
Description: 10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
Study: NCT02720159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Osseintegrated Prosthesis
Study: NCT02907437

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: (450 mg/day)
Study: NCT03124147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroconn Eldith stimulator by Magstim
Description: Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroconn Eldith stimulator by Magstim
Description: Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuroconn Eldith stimulator by Magstim
Description: Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuroconn Eldith stimulator by Magstim
Description: Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
Study: NCT00994214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM 23A760
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM 23A760
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM 23A760
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM 23A760
Description: Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
Study: NCT01958398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promillekoll
Description: Smartphone app monitoring alcohol use with feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartyPlanner
Description: Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
Study: NCT04013152

Intervention type: OTHER
Intervention: Clinical database
Description: Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
Study: NCT01937715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Description: The RP2D/MTD dose of FOLFIRI regimen every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Full dose FOLFIRI regimen every 2 weeks
Study: NCT01922856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LTR192G with dscCfaE
Description: Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Controls only receive challenge
Study: NCT03634722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHENIX4-8-8 PLUS
Description: transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
Study: NCT03581669

Intervention type: DEVICE
Intervention: Cerclage and total hip arthroplasty
Description: acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
Study: NCT03772093

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trabert current
Description: Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual massage
Description: Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
Study: NCT04626700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP
Description: iNAP for the treatment of OSA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP for the treatment of OSA
Study: NCT02163317

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo MRI-guided focal SRS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo staging MRI with contrast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum Prostate Antigen Test
Description: Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Exam
Description: Exam of rectal health. Performed every three months for up to two years throughout the study.
Study: NCT01555398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions
Description: The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions
Description: The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
Study: NCT02690337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1123
Description: starting intravenous (IV) dose of 0.1 mg/kg.
Study: NCT02163317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite
Description: This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
Study: NCT04265300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creative Roots
Description: The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
Study: NCT03633864

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
Study: NCT03331731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study: NCT03370185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
Study: NCT01648998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: single dose 500 mg, capsule
Study: NCT03055546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration of oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasal administration of placebo
Study: NCT02595606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Sodium Hyaluronate
Description: five times per day for the intervention of eye drop
Study: NCT00763594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Relational Therapy
Description: 16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Relational Therapy
Description: 16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: 16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
Study: NCT03828188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Ginseng Concentrated Powder
Description: Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Ginseng Concentrated Powder
Description: Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 12 weeks.
Study: NCT01648998

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01885663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood therapy
Description: Intravascular umbilical cord blood therapy
Study: NCT03627715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propagermanium
Description: Immediate release capsule
Study: NCT01485107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT04423419

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PENG block
Description: The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fascia iliaca block
Description: ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%

Intervention type: OTHER
Group type: OTHER
Intervention: IV analgesia
Description: IV analgesia
Study: NCT04268056

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of skin culture samples
Description: Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
Study: NCT01813305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSTC1
Description: vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CSTC1 Matched vehicle
Study: NCT03702387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard intravenous regional anesthesia (IVRA) with reapplication of esmach
Description: his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
Study: NCT01299142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGI-101-1A6
Description: anti-TSG101 human monoclonal antibody, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FGI-101-1A6
Description: anti-TSG101 human monoclonal antibody, single dose
Study: NCT01368237

Intervention type: RADIATION
Intervention: Computed tomography scan
Description: Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
Study: NCT04460833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback modalities given through an augmented reality headset
Description: All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.